Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 18, 2020 16:05 ET | Source: Galera Therapeutics

Galera Therapeutics to Host Virtual KOL Event on Cisplatin-Induced Chronic Kidney Disease

MALVERN, Pa., May 18, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
May 13, 2020 17:19 ET | Source: Galera Therapeutics

Galera Therapeutics Announces New Data from the Phase 2b Trial on the Effect of Avasopasem Manganese on Cisplatin-Induced Chronic Kidney Disease to be Presented at ASCO 2020 Virtual Scientific Program

MALVERN, Pa., May 13, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
May 12, 2020 07:00 ET | Source: Galera Therapeutics

Galera Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Updates

ROMAN Phase 3 Trial Topline Data Readout Guidance Updated to 2H21 Due to Impact of COVID-19 Amendment to Royalty Agreement for Additional $37.5M Extends Cash Runway into 2H22 Locally Advanced...
May 05, 2020 08:00 ET | Source: Galera Therapeutics

Galera Therapeutics to Present at BofA Securities 2020 Health Care Conference

MALVERN, Pa., May 05, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
April 30, 2020 16:15 ET | Source: Galera Therapeutics

Galera Therapeutics Announces Presentation of Avasopasem Manganese Data at ASCO 2020 Virtual Scientific Program

MALVERN, Penn., April 30, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
April 02, 2020 08:00 ET | Source: Galera Therapeutics

Galera Therapeutics Appoints Linda B. West to Board of Directors

MALVERN, Pa., April 02, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
March 10, 2020 07:00 ET | Source: Galera Therapeutics

Galera Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Accomplishments

- Expanded Lead Product Candidate Avasopasem Manganese into Second Radiation Toxicity Indication - - Presented Data Demonstrating Avasopasem Manganese Maintained Anti-Cancer Benefit of...
February 27, 2020 16:05 ET | Source: Galera Therapeutics

Galera Therapeutics Announces Avasopasem Manganese (GC4419) Maintained Anti-Cancer Benefit of Chemoradiotherapy for Head and Neck Cancer While Substantially Reducing Radiation-Induced Severe Oral Mucositis

MALVERN, Pa., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
February 24, 2020 08:00 ET | Source: Galera Therapeutics

Galera Therapeutics Announces Presentation of Avasopasem Manganese (GC4419) Two-Year Tumor Outcomes Data at 2020 Multidisciplinary Head and Neck Cancers Symposium

MALVERN, Pa., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
February 19, 2020 08:00 ET | Source: Galera Therapeutics

Galera Therapeutics to Present at Cowen and Company 40th Annual Health Care Conference

MALVERN, Pa., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right